BSEResult4d ago · 14 Nov 2026, 04:27 pm

Declaration of Financial results for quarter and half year ended on September 30, 2026

Orchid Pharma Ltd · 524372

✦ AI Summary▼ NegativeResults

Orchid Pharma Ltd has declared its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The company's net sales income for the quarter stood at ₹34,126.66 lakhs, a decrease of 14.5% from the same period last year. The company's profit before tax for the quarter was ₹2,683.69 lakhs, a decrease of 27.5% from the same period last year.

Analysis Scores

Earnings Impact4/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk5/10
Liquidity Impact8/10
Market Sentiment3/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Orchid Pharma Ltd - 524372 - Declaration Of Financial Results For Quarter And Half Year Ended On September 30, 2026

Attachments (1)

📄

4d571749-205a-4fee-b8d2-6912c220b485.pdf

pdf

Download →
View document text
OrchidPharm~W -- A Dhanuka Group Company ------------------------------------- November 14, 2026 National Stock Exchange of India Limited, SSE Limited Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Dalal Bandra (E), Mumbai-400051 Street, Fort, Mumbai-400001 Symbol: ORCHPHARMA Scrip Code: 524372 Subject: Outcome of Board Meeting - Orchid Pharma Limited ("the Company") Dear SirjMadam, With reference to the captioned subject and pursuant to Regulation 30 read with Part A Para A of Schedule III and Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations), as amended read with SEBIj HOj49j14j14(7)2025-CFD-POD2jlj3762j2026, dated January 30, 2026, SEBI Circular no. SEBljHOjCFDjCFD-PoD-2jCIRjPj2024j185 dated December 31, 2024 and in continuation to the prior intimation given by the Company on November 11, 2026 for scheduling the Board Meeting, we would like to inform you that the Board of Directors of the Company at its meeting held today i.e. November 14, 2026 (commenced at 12:00 Noon (1ST) and concluded at 04:00 P.M. (1ST) has, inter-alia, considered and approved the Unaudited limited reviewed Standalone & Consolidated Financial Results of the Company for quarter and half year ended on September 30, 2026 along with the auditors' limited review reports on standalone and consolidated quarterly financial results, issued by Mjs. Singhi & Co., Statutory Auditors of the Company, enclosed herewith as Annexure-I. You are requested to take the above intimations on record. Thanking You, For Orchid Pharm~t'"~ite ' • f£J r- <' ~(Gurgaon\= 'I..., Ki ya 0-- -- '"l") Co any Secretary & CO!!J,piance Officer Mem. No. Fl0698 Encl. as above +91-44-27444471/72/73 corporate@orchidpharma.com orchidpharma.com CIN: L24222TN1992PLC022994 Registered Office: Corporate Office: Orchid Pharma Limited 15th Floor, Tower 1, DLF Corporate Greens, Sector 74A, Plot Nos. 121-128, 128A-133, 138-151, 159-164, SIDCO Industrial Estate, Gurugram - 122004, Haryana, India Alathur, Chengalpattu Dist - 603110, Tamil Nadu, India. Annexure-I Orchid Pharma Limited Regd Office: Plot Nos. 121 -128, 128A -133,138 -151,159 -164, SIDGO Industrial Estate, Alathur, Ghen9alpatlu District -603110, Tamil Nadu, India Ph. +91 -44 -2744 4471 -78 Email id: corporate@orchidpharma.com Website: www.orchidpharma.com GIN: L24222TN1992PLC022994 Statement of Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30,2026 (All amounts are in lakhs of Indian Rupees, unless otherwise stated) S, No, Particulars Standalone financial results Consolidated financial results For the quarter ended Six month ended For the year ended For the quarter ended Six month ended For the year ended Sep 30, 2026 June 30, 2026 Sep 30, 2025 Sep 30, 2026 Sep 30, 2025 March 31, 2026 Sep 30, 2026 June 30, 2026 Sep 30, 2025 Sep 30, 2026 Sep 30, 2025 March 31, 2026 (Unaudited) (Unaudited) Revised (Unaudited) Revised Revised (Unaudited) (Unaudited) Revised (Unaudited) Revised Revised (Unaudited) (Unaudited) (Audited) (Unaudited) (Unaudited) (Audited) (Refer Note 6) (Refer Note 6) (Refer Note 6) (Refer Note 6) (Refer Note 6) (Refer Note 6) Income from Operations 1 Net Sales' Income from operations 34,126.66 30,417.13 29,845.86 64,543.79 56,164.44 1,23,277.84 34126.66 30,417.13 29,845.86 64543.79 56,164.44 123277.84 2 Other Income 2,863.08 1,004.72 1,628.93 3,867.80 3,234.19 5,648.69 1775.58 182.84 1,163.85 1958.42 2,320.83 3641.83 3 Total Income (1+2) 36,989,74 31,421,85 31,474.79 68,411.59 59,398,63 1,28,926,53 35,902,24 30,599.97 31,009.71 66,502.21 58,485.27 1,26,919.67 4 Expenses Cost of materials consumed 24,596.17 20,642,20 17,205.03 45,238.37 37,574.81 77,139.16 24596.17 20,642.20 17,205.03 45238.37 37,574.81 77139.16 Changes in inventories of raw material, work-in-progress, stock-in- (3,895.02) (272.47) 3,478.90 (4,167.49) 1,369.43 7,138.39 (3,895.02) (272.47) 3,478.90 (4,167.49) 1,369.43 7138.39 trade and finished goods Purchases of Stock in trade 142.24 60.65 17.34 202.89 96.13 168.72 142.24 60.65 17.34 202.89 96.13 168.72 Employee benefit expenses 3,268.50 2,675.81 3,063.70 5,944.31 5,833.50 11,432.05 3140.52 2,803.79 3,144.07 5944.31 5,913.87 11765.46 Finance costs 366.12 221.23 256.81 587.35 485.29 896.15 364.33 223.02 256.81 587.35 485.29 898.43 Depreciation and amortization expense 1,131.64 1,09).16 1,070.25 2,221.80 2,123.71 4,335.60 1141.19 1,094.91 1,081.26 2236.1 2,134.72 4324.63 Other expenses 7,704.16 5,m.55 5,691.96 13,514.71 11,465.50 23,621.17 7729.12 5.782.92 5,692.10 13512.04 11,465.98 23708.71 Total EKpenses 33,313,81 30,228,13 30,783,99 63,541.94 58,948,37 1,24,731,24 33,218.55 30,335,02 30,875,51 63,553,57 59,040,23 1,25,143,50 5 Profit I (Loss) before exceptional items and tax (H) 3,675,93 1,193,72 690,80 4,869,65 450,26 4,195,29 2,683.69 264,95 134,20 2,948,64 (554,96) 1,776,17 6 Exceplional items (refer Note no.3) (733.29) (733.29) 7 Profit I (La ••) before tax (5+6) 3,675,93 1,19],72 690,80 4,869,65 450,26 3,462,00 2,683,69 264,95 134.20 2,948.64 (554,96) 1,042,88 8 TaK eKpense Current lax Tax adjustments of earliear years Deferred tax (4.49) 7.23 (14.83) 2.74 (14.83) (19.16) Total Tax Expenses (4.49) 7.23 (14.83) 2.74 (14.83) (19.16) 9 Profit I (Loss) for the period before share of profit of Associates (7·8) 3,675,93 1,193,/2 690.80 4,869.65 450,26 3,462,00 2,688.18 257.72 149,03 2,945,90 (540,13) 1,062,04 Statement of Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026 (Contd ... ) S. No. Particulars Standalone financial results Consolidated financial results For the quarter ended Six month ended Forthe For the quarter ended Six month ended Forthe year ended year ended Sep 30, 2026 June 30, 2026 Sep 30, 2025 Sep 30, 2026 Sap 30, 2025 March 31, 2026 Sep 30, 2026 June 30, 2026 Sep 30, 2025 Sep 30, 2026 Sep 30, 2025 March 31, 2026 (Unaudited) (Unaudited) Revised (Unaudited) Revised Revised (Unaudited) (Unaudited) Revised (Unaudited) Revised Revised (Unaudited) (Unaudited) (Audited) (Unaudited) (Unaudited) (Audited) (Refer Note 6) (Refer Note 6) (Refer Note 6) (Refer Note 6) (Refer Note 6) (Refer Note 6) 10 Profit I (loss) for the period before share of profit of Associates 3,675.93 1,193.72 690.80 4,869.65 450.26 3,462.00 2,688.18 257.72 149.03 2,945.90 (540.13) 1,062.04 11 Add: Share of Profit/ (loss) of Associates 171.23 64.72 (23B.B7) 235.95 (11B.93) (66.13) 12 Profit I (Loss) for the period (10+11) 3,675.93 1,193.72 690.80 4,869.65 450.26 3,462.00 2,859.41 322.44 (89.84) 3,181.85 (659.06) 995.91 13 Other comprehensive income, net of income tax a) (i) items that will not be reclassified to profit or loss (30.70) 0.64 (39.45) (30.06) (54.93) 131.76 (30.70) 0.64 (39.45) (30.06) (54.93) 131.76 (ii) income tax relating to items that will not be reclassified to profit or loss b) (i) items that will be reclassified to profit or loss (ii) income tax relating to items that will be reclassified to profit or loss Total other comprehensive Incomel (loss), net of Income tax (30.70) 0.64 (39.45) (30.06) (54.93) 131.76 (30.70) 0.64 (39.45) (30.06) (54.93) 131.76 14 Total comprehensive incomel (Loss) for the period (12+13) 3,645.23 1,194.36 651.35 4,839.59 395.33 3,593.76 2,828.71 323.08 (129.29) 3,151.79 (713.99) 1,127.67 I~ 15 Paid·up equity share capital 5.988.52 5.988.52 5,988.52 5,988.52 5,988.52 5.988.52 5.988.52 5,988.52 5,988.52 5.988.52 5,988.52 5.988.52 (Including Shares pending allotment on account of Merger) Other Equity 1,58,679.07 1.50,442.18 Face value per share (Rs) 10.00 10.00 10.00 10.00 10.00 10.00 10.00 to.OO 10.00 10.00 10.00 10.00 16 Earnings per equity share ": -Basic (Rs.) 6.14 1.99 1.15 8.13 0.75 5.78 4.77 0.54 (0.15) 5.31 (1.10) 1.66 . Diluted (Rs.) 6.14 1.99 1.15 8.13 0.75 5.78 4.77 0.54 (0.15) 5.31 (1.10) 1.66 • I EPS for the quarters are not annualised c,~1 cI c. : " : t. 0 . V (r ) '.U - [Showing first 8,000 characters — download PDF for full document]